Differential vulnerability of neurons in Huntington’s disease: the role of cell type‐specific features
暂无分享,去创建一个
Jeffrey H Kordower | J. Kordower | S. Brady | G. Morfini | Ina Han | YiMei You | Scott T Brady | Gerardo A Morfini | Yimei You | I. Han
[1] L. Menalled,et al. Knock-in mouse models of Huntington’s disease , 2005, NeuroRX.
[2] Chuan-en Wang,et al. Mutant Huntingtin in Glial Cells Exacerbates Neurological Symptoms of Huntington Disease Mice* , 2010, The Journal of Biological Chemistry.
[3] Y. Barde,et al. Global Deprivation of Brain-Derived Neurotrophic Factor in the CNS Reveals an Area-Specific Requirement for Dendritic Growth , 2010, The Journal of Neuroscience.
[4] Peng Yu,et al. Altered white matter microstructure in the corpus callosum in Huntington's disease: Implications for cortical “disconnection” , 2010, NeuroImage.
[5] A. Orr,et al. Impaired mitochondrial trafficking in Huntington's disease. , 2010, Biochimica et biophysica acta.
[6] Yuyu Song,et al. Axonal Transport Defects in Neurodegenerative Diseases , 2009, The Journal of Neuroscience.
[7] N. Déglon,et al. Diminished hippocalcin expression in Huntington’s disease brain does not account for increased striatal neuron vulnerability as assessed in primary neurons , 2009, Journal of neurochemistry.
[8] V. Silani,et al. Huntington's disease: The current state of research with peripheral tissues , 2009, Experimental Neurology.
[9] Chun-Fang Huang,et al. Pathogenic Huntingtin Inhibits Fast Axonal Transport by Activating JNK3 and Phosphorylating Kinesin , 2009, Nature Neuroscience.
[10] P. Reddy,et al. Mitochondrial structural and functional dynamics in Huntington's disease , 2009, Brain Research Reviews.
[11] J. Marsh,et al. Live axonal transport disruption by mutant huntingtin fragments in Drosophila motor neuron axons , 2009, Neurobiology of Disease.
[12] Kurt E. Weaver,et al. Longitudinal diffusion tensor imaging in Huntington's Disease , 2009, Experimental Neurology.
[13] N. Déglon,et al. Implication of the JNK pathway in a rat model of Huntington's disease , 2009, Experimental Neurology.
[14] M. Farrer,et al. DCTN1 mutations in Perry syndrome , 2009, Nature Genetics.
[15] L. Goldstein,et al. Enhanced Sensitivity of Striatal Neurons to Axonal Transport Defects Induced by Mutant Huntingtin , 2008, The Journal of Neuroscience.
[16] S. Browne,et al. Mitochondria and Huntington's Disease Pathogenesis , 2008, Annals of the New York Academy of Sciences.
[17] R. Atwal,et al. Huntington’s disease: revisiting the aggregation hypothesis in polyglutamine neurodegenerative diseases , 2008, The FEBS journal.
[18] Paul Greengard,et al. Cell type–specific regulation of DARPP-32 phosphorylation by psychostimulant and antipsychotic drugs , 2008, Nature Neuroscience.
[19] Carlos Cepeda,et al. Full-Length Human Mutant Huntingtin with a Stable Polyglutamine Repeat Can Elicit Progressive and Selective Neuropathogenesis in BACHD Mice , 2008, The Journal of Neuroscience.
[20] Brendan H. Lee,et al. Suppression of neuropil aggregates and neurological symptoms by an intracellular antibody implicates the cytoplasmic toxicity of mutant huntingtin , 2008, The Journal of cell biology.
[21] L. Massieu,et al. Excitotoxic neuronal death and the pathogenesis of Huntington's disease. , 2008, Archives of Medical Research.
[22] He Li,et al. N-Terminal Mutant Huntingtin Associates with Mitochondria and Impairs Mitochondrial Trafficking , 2008, The Journal of Neuroscience.
[23] Yuwu Jiang,et al. Clinical and genetic study in Chinese patients with Alexander disease. , 2008 .
[24] A. Jennifer Morton,et al. Atrophy and degeneration in sciatic nerve of presymptomatic mice carrying the Huntington's disease mutation , 2008, Brain Research.
[25] J. Vonsattel,et al. Huntington disease models and human neuropathology: similarities and differences , 2007, Acta Neuropathologica.
[26] J. Cha,et al. Transcriptional signatures in Huntington's disease , 2007, Progress in neurobiology.
[27] Xi Chen,et al. Dopaminergic Signaling and Striatal Neurodegeneration in Huntington's Disease , 2007, The Journal of Neuroscience.
[28] H. Zoghbi,et al. Trinucleotide repeat disorders. , 2007, Annual review of neuroscience.
[29] M. MacDonald,et al. Unbiased Gene Expression Analysis Implicates the huntingtin Polyglutamine Tract in Extra-mitochondrial Energy Metabolism , 2007, PLoS genetics.
[30] Wenya Linda Bi,et al. Triplet repeat mutation length gains correlate with cell-type specific vulnerability in Huntington disease brain. , 2007, Human molecular genetics.
[31] J. Kordower,et al. Neurturin gene therapy improves motor function and prevents death of striatal neurons in a 3-nitropropionic acid rat model of Huntington's disease , 2007, Neurobiology of Disease.
[32] Carlos Cepeda,et al. The corticostriatal pathway in Huntington's disease , 2007, Progress in Neurobiology.
[33] F. Walker. Huntington's disease. , 2007, Lancet.
[34] E. Cattaneo,et al. Role of brain-derived neurotrophic factor in Huntington's disease , 2007, Progress in Neurobiology.
[35] Xiao-Jiang Li. The early cellular pathology of Huntington’s disease , 1999, Molecular Neurobiology.
[36] Jeffrey H Kordower,et al. Animal models of Huntington's disease. , 2007, ILAR journal.
[37] O. Steward,et al. Differential susceptibility to striatal neurodegeneration induced by quinolinic acid and kainate in inbred, outbred and hybrid mouse strains , 2006, The European journal of neuroscience.
[38] E. Thomas,et al. Striatal specificity of gene expression dysregulation in Huntington's disease , 2006, Journal of neuroscience research.
[39] J. Alberch,et al. Cellular and molecular mechanisms involved in the selective vulnerability of striatal projection neurons in Huntington's disease. , 2006, Histology and histopathology.
[40] Dale E. Bredesen,et al. Cell death in the nervous system , 2006, Nature.
[41] K. Jellinger. Challenges in neuronal apoptosis. , 2006, Current Alzheimer research.
[42] H. McBride,et al. Mitochondria: More Than Just a Powerhouse , 2006, Current Biology.
[43] G. Pigino,et al. JNK mediates pathogenic effects of polyglutamine-expanded androgen receptor on fast axonal transport , 2006, Nature Neuroscience.
[44] P. Klivényi,et al. Behaviour changes in a transgenic model of Huntington's disease , 2006, Behavioural Brain Research.
[45] M. Mattson,et al. Ageing and neuronal vulnerability , 2006, Nature Reviews Neuroscience.
[46] Katalin Illes,et al. Mutant huntingtin alters MAPK signaling pathways in PC12 and striatal cells: ERK1/2 protects against mutant huntingtin-associated toxicity. , 2006, Human molecular genetics.
[47] L. Raymond,et al. Selective neuronal degeneration in Huntington's disease. , 2006, Current topics in developmental biology.
[48] S. Dunnett,et al. Pharmaceutical, cellular and genetic therapies for Huntington's disease. , 2006, Clinical science.
[49] A. Parent,et al. Relationship between axonal collateralization and neuronal degeneration in basal ganglia. , 2006, Journal of neural transmission. Supplementum.
[50] M. MacDonald,et al. HD CAG repeat implicates a dominant property of huntingtin in mitochondrial energy metabolism. , 2005, Human molecular genetics.
[51] C. Pagès,et al. Unraveling a role for dopamine in Huntington's disease: the dual role of reactive oxygen species and D2 receptor stimulation. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[52] K. Fischbeck,et al. Distal spinal and bulbar muscular atrophy caused by dynactin mutation , 2005, Annals of neurology.
[53] G. Pigino,et al. Polyglutamine expansion diseases: failing to deliver. , 2005, Trends in molecular medicine.
[54] E. Wagner,et al. Specific pathophysiological functions of JNK isoforms in the brain , 2005, The European journal of neuroscience.
[55] P. Wesseling,et al. Expression pattern of apoptosis-related markers in Huntington’s disease , 2005, Acta Neuropathologica.
[56] Bin Zhang,et al. Axonal transport defects: a common theme in neurodegenerative diseases , 2005, Acta Neuropathologica.
[57] J. Caboche,et al. Expanded huntingtin activates the C-JUN N TERMINAL KINASE/C-JUN pathway prior to aggregate formation in striatal neurons in culture , 2004, Neuroscience.
[58] Carlos Cepeda,et al. Genetic mouse models of Huntington's and Parkinson's diseases: illuminating but imperfect , 2004, Trends in Neurosciences.
[59] Mark R. Segal,et al. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death , 2004, Nature.
[60] Shihua Li,et al. Huntington and its Role in Neuronal Degeneration , 2004, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.
[61] E. Seeberg,et al. Mutant Huntingtin Impairs Axonal Trafficking in Mammalian Neurons In Vivo and In Vitro , 2004, Molecular and Cellular Biology.
[62] J. Kordower,et al. Early changes in Huntington’s disease patient brains involve alterations in cytoskeletal and synaptic elements , 2004, Journal of neurocytology.
[63] G. Mengod,et al. Brain-Derived Neurotrophic Factor Regulates the Onset and Severity of Motor Dysfunction Associated with Enkephalinergic Neuronal Degeneration in Huntington's Disease , 2004, The Journal of Neuroscience.
[64] Fabrice P Cordelières,et al. Huntingtin Controls Neurotrophic Support and Survival of Neurons by Enhancing BDNF Vesicular Transport along Microtubules , 2004, Cell.
[65] Sarah A. J. Reading,et al. Functional brain changes in presymptomatic Huntington's disease , 2004, Annals of neurology.
[66] M. Beal,et al. Experimental therapeutics in transgenic mouse models of Huntington's disease , 2004, Nature Reviews Neuroscience.
[67] J. Gorski,et al. Early Striatal Dendrite Deficits followed by Neuron Loss with Advanced Age in the Absence of Anterograde Cortical Brain-Derived Neurotrophic Factor , 2004, The Journal of Neuroscience.
[68] R. Bonelli,et al. A review of the treatment options for Huntington’s disease , 2004, Expert opinion on pharmacotherapy.
[69] J. Littleton,et al. Cytoplasmic aggregates trap polyglutamine-containing proteins and block axonal transport in a Drosophila model of Huntington's disease. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[70] M. Tymianski,et al. Molecular mechanisms underlying specificity of excitotoxic signaling in neurons. , 2004, Current molecular medicine.
[71] D. Mann,et al. The topographic distribution of brain atrophy in Huntington's disease and progressive supranuclear palsy , 2004, Acta Neuropathologica.
[72] H. Heinsen,et al. Cortical and striatal neurone number in Huntington's disease , 2004, Acta Neuropathologica.
[73] Elizabeth Evans,et al. Dramatic tissue-specific mutation length increases are an early molecular event in Huntington disease pathogenesis. , 2003, Human molecular genetics.
[74] Marjan S. Bolouri,et al. Integrated Analysis of Protein Composition, Tissue Diversity, and Gene Regulation in Mouse Mitochondria , 2003, Cell.
[75] Harry T Orr,et al. Regional differences of somatic CAG repeat instability do not account for selective neuronal vulnerability in a knock-in mouse model of SCA1. , 2003, Human molecular genetics.
[76] Christine Van Broeckhoven,et al. Pathogenesis of polyglutamine disorders: aggregation revisited. , 2003, Human molecular genetics.
[77] J. Brandt,et al. Predictors of neuropathological severity in 100 patients with Huntington's disease , 2003, Annals of neurology.
[78] Scott T. Brady,et al. Neuropathogenic Forms of Huntingtin and Androgen Receptor Inhibit Fast Axonal Transport , 2003, Neuron.
[79] Richard G. Brusch,et al. Disruption of Axonal Transport by Loss of Huntingtin or Expression of Pathogenic PolyQ Proteins in Drosophila , 2003, Neuron.
[80] D. Rubinsztein,et al. Huntington's disease: molecular basis of neurodegeneration , 2003, Expert Reviews in Molecular Medicine.
[81] M. Okun. Huntington’s Disease: What We Learned From the Original Essay , 2003, The neurologist.
[82] A. Spada,et al. Polyglutamines Placed into Context , 2003, Neuron.
[83] I. Mitchell,et al. The Differential Susceptibility of Specific Neuronal Populations: Insights from Huntington's Disease , 2003, IUBMB life.
[84] K. Merienne,et al. Polyglutamine Expansion Induces a Protein-damaging Stress Connecting Heat Shock Protein 70 to the JNK Pathway* , 2003, The Journal of Biological Chemistry.
[85] Yasushi Hiraoka,et al. Mutations in Dynein Link Motor Neuron Degeneration to Defects in Retrograde Transport , 2003, Science.
[86] M. Vila,et al. Neurological diseases: Targeting programmed cell death in neurodegenerative diseases , 2003, Nature Reviews Neuroscience.
[87] Thomas Walther,et al. Transgenic rat model of Huntington's disease. , 2003, Human molecular genetics.
[88] Shin J. Oh,et al. Mutant dynactin in motor neuron disease , 2003, Nature Genetics.
[89] Carlos Cepeda,et al. Transient and Progressive Electrophysiological Alterations in the Corticostriatal Pathway in a Mouse Model of Huntington's Disease , 2003, The Journal of Neuroscience.
[90] M. Pericak-Vance,et al. A kinesin heavy chain (KIF5A) mutation in hereditary spastic paraplegia (SPG10). , 2002, American journal of human genetics.
[91] D. Rubinsztein,et al. Glycogen Synthase Kinase-3β Inhibitors Prevent Cellular Polyglutamine Toxicity Caused by the Huntington's Disease Mutation* , 2002, The Journal of Biological Chemistry.
[92] M. Birnbaum,et al. Akt1 Regulates a JNK Scaffold during Excitotoxic Apoptosis , 2002, Neuron.
[93] G. Bates,et al. Abnormal Phosphorylation of Synapsin I Predicts a Neuronal Transmission Impairment in the R6/2 Huntington's Disease Transgenic Mice , 2002, Molecular and Cellular Neuroscience.
[94] James R. Burke,et al. Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines , 2002, Nature Neuroscience.
[95] Fabrice P Cordelières,et al. The IGF-1/Akt pathway is neuroprotective in Huntington's disease and involves Huntingtin phosphorylation by Akt. , 2002, Developmental cell.
[96] Christopher A. Ross,et al. Lentiviral-Mediated Delivery of Mutant Huntingtin in the Striatum of Rats Induces a Selective Neuropathology Modulated by Polyglutamine Repeat Size, Huntingtin Expression Levels, and Protein Length , 2002, The Journal of Neuroscience.
[97] Emmanuel Brouillet,et al. The Mitochondrial Toxin 3-Nitropropionic Acid Induces Striatal Neurodegeneration via a c-Jun N-Terminal Kinase/c-Jun Module , 2002, The Journal of Neuroscience.
[98] S. Brady,et al. Regulation of Kinesin: Implications for Neuronal Development , 2001, Developmental Neuroscience.
[99] M. Chesselet,et al. Electrophysiological and morphological changes in striatal spiny neurons in R6/2 Huntington's disease transgenic mice. , 2001, Journal of neurophysiology.
[100] C. Cepeda,et al. Changes in Cortical and Striatal Neurons Predict Behavioral and Electrophysiological Abnormalities in a Transgenic Murine Model of Huntington's Disease , 2001, The Journal of Neuroscience.
[101] J. Schiefer,et al. Evaluation of R6/2 HD transgenic mice for therapeutic studies in Huntington's disease: behavioral testing and impact of diabetes mellitus , 2001, Behavioural Brain Research.
[102] C. Cepeda,et al. NMDA receptor function in mouse models of Huntington disease , 2001, Journal of neuroscience research.
[103] H Li,et al. Huntingtin Aggregate-Associated Axonal Degeneration is an Early Pathological Event in Huntington's Disease Mice , 2001, The Journal of Neuroscience.
[104] A. Gordon,et al. Objective assessment of progression in Huntington’s disease: A 3-year follow-up study , 2001, Neurology.
[105] I. Kanazawa,et al. Age‐dependent and tissue‐specific CAG repeat instability occurs in mouse knock‐in for a mutant Huntington's disease gene , 2001, Journal of neuroscience research.
[106] Blair R. Leavitt,et al. Loss of Huntingtin-Mediated BDNF Gene Transcription in Huntington's Disease , 2001, Science.
[107] Gareth W. Price,et al. Activated JNK Phosphorylates the C-terminal Domain of MLK2 That Is Required for MLK2-induced Apoptosis* , 2001, The Journal of Biological Chemistry.
[108] K. Sieradzan,et al. The selective vulnerability of nerve cells in Huntington's disease , 2001, Neuropathology and applied neurobiology.
[109] E. Tolosa,et al. Expression of Brain-Derived Neurotrophic Factor in Cortical Neurons Is Regulated by Striatal Target Area , 2001, The Journal of Neuroscience.
[110] A. Tobin,et al. Huntington's disease: the challenge for cell biologists. , 2000, Trends in cell biology.
[111] A. Parent,et al. Chemical anatomy of striatal interneurons in normal individuals and in patients with Huntington’s disease , 2000, Brain Research Reviews.
[112] P. Shelbourne,et al. Dramatic mutation instability in HD mouse striatum: does polyglutamine load contribute to cell-specific vulnerability in Huntington's disease? , 2000, Human molecular genetics.
[113] S B Dunnett,et al. Abnormal Synaptic Plasticity and Impaired Spatial Cognition in Mice Transgenic for Exon 1 of the Human Huntington's Disease Mutation , 2000, The Journal of Neuroscience.
[114] P. Greengard,et al. Severe deficiencies in dopamine signaling in presymptomatic Huntington's disease mice. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[115] W. Maragos,et al. Neuronal cell death in Huntington’s disease: a potential role for dopamine , 2000, Trends in Neurosciences.
[116] C A Ross,et al. Decreased expression of striatal signaling genes in a mouse model of Huntington's disease. , 2000, Human molecular genetics.
[117] J. Penney,et al. Expression of NMDA receptor subunit mRNAs in neurochemically identified projection and interneurons in the human striatum , 2000, The Journal of comparative neurology.
[118] G. Sobue,et al. An autopsy case with clinically and molecular genetically diagnosed Huntington's disease with only minimal non-specific neuropathological findings. , 2000, Clinical neuropathology.
[119] S. Suhr,et al. Intraneuronal Aggregate Formation and Cell Death after Viral Expression of Expanded Polyglutamine Tracts in the Adult Rat Brain , 2000, The Journal of Neuroscience.
[120] S. Hersch,et al. Huntingtin aggregates may not predict neuronal death in Huntington's disease , 1999 .
[121] A. Cooper,et al. The selective vulnerability of striatopallidal neurons , 1999, Progress in Neurobiology.
[122] A. Morton,et al. Selective Discrimination Learning Impairments in Mice Expressing the Human Huntington's Disease Mutation , 1999, The Journal of Neuroscience.
[123] M. Beal,et al. Bioenergetics in Huntington's Disease , 1999, Annals of the New York Academy of Sciences.
[124] J. D. de Yébenes,et al. Clinical correlation of striatal 1H MRS changes in Huntington’s disease , 1999, Neurology.
[125] Shihua Li,et al. Cellular Defects and Altered Gene Expression in PC12 Cells Stably Expressing Mutant Huntingtin , 1999, The Journal of Neuroscience.
[126] G P Bates,et al. Ultrastructural localization and progressive formation of neuropil aggregates in Huntington's disease transgenic mice. , 1999, Human molecular genetics.
[127] D. Goebel,et al. NMDA receptor subunit gene expression in the rat brain: a quantitative analysis of endogenous mRNA levels of NR1Com, NR2A, NR2B, NR2C, NR2D and NR3A. , 1999, Brain research. Molecular brain research.
[128] H. Heinsen,et al. Nerve cell loss in the thalamic mediodorsal nucleus in Huntington’s disease , 1999, Acta Neuropathologica.
[129] Alfredo Berardelli,et al. Pathophysiology of chorea and bradykinesia in Huntington's disease , 1999, Movement disorders : official journal of the Movement Disorder Society.
[130] Claire-Anne Gutekunst,et al. Nuclear and Neuropil Aggregates in Huntington’s Disease: Relationship to Neuropathology , 1999, The Journal of Neuroscience.
[131] D. Surmeier,et al. Cellular Localization of Huntingtin in Striatal and Cortical Neurons in Rats: Lack of Correlation with Neuronal Vulnerability in Huntington’s Disease , 1999, The Journal of Neuroscience.
[132] J. Penney,et al. Axonal transport of N-terminal huntingtin suggests early pathology of corticostriatal projections in Huntington disease. , 1999, Journal of neuropathology and experimental neurology.
[133] Y. Liu. Expression of Polyglutamine-expanded Huntingtin Activates the SEK1-JNK Pathway and Induces Apoptosis in a Hippocampal Neuronal Cell Line* , 1998, The Journal of Biological Chemistry.
[134] Steven Finkbeiner,et al. Huntingtin Acts in the Nucleus to Induce Apoptosis but Death Does Not Correlate with the Formation of Intranuclear Inclusions , 1998, Cell.
[135] K. Neve,et al. D2 Dopamine Receptors Stimulate Mitogenesis Through Pertussis Toxin‐Sensitive G Proteins and Ras‐Involved ERK and SAP/JNK Pathways in Rat C6‐D2L Glioma Cells , 1998, Journal of neurochemistry.
[136] A. Tobin,et al. Metabolic Compromise with Systemic 3-Nitropropionic Acid Produces Striatal Apoptosis in Sprague–Dawley Rats but Not in BALB/c ByJ Mice , 1998, Experimental Neurology.
[137] Xuechu Zhen,et al. D1 dopamine receptor agonists mediate activation of p38 mitogen-activated protein kinase and c-Jun amino-terminal kinase by a protein kinase A-dependent mechanism in SK-N-MC human neuroblastoma cells. , 1998, Molecular pharmacology.
[138] J. Mandel,et al. A cellular model that recapitulates major pathogenic steps of Huntington's disease. , 1998, Human molecular genetics.
[139] Michael R. Hayden,et al. The Influence of Huntingtin Protein Size on Nuclear Localization and Cellular Toxicity , 1998, The Journal of cell biology.
[140] Shihua Li,et al. Aggregation of N-terminal huntingtin is dependent on the length of its glutamine repeats. , 1998, Human molecular genetics.
[141] C A Ross,et al. Truncated N-terminal fragments of huntingtin with expanded glutamine repeats form nuclear and cytoplasmic aggregates in cell culture. , 1998, Human molecular genetics.
[142] S. W. Davies,et al. Intranuclear Neuronal Inclusions in Huntington's Disease and Dentatorubral and Pallidoluysian Atrophy: Correlation between the Density of Inclusions andIT15CAG Triplet Repeat Length , 1998, Neurobiology of Disease.
[143] Y. Smith,et al. Microcircuitry of the direct and indirect pathways of the basal ganglia. , 1998, Neuroscience.
[144] S. W. Davies,et al. Nuclear inclusions in Huntington's disease. , 1997, Trends in cell biology.
[145] K Naujoks,et al. Regional, developmental and interspecies expression of the four NMDAR2 subunits, examined using monoclonal antibodies. , 1997, Brain research. Molecular brain research.
[146] P. Rakic,et al. Absence of excitotoxicity-induced apoptosis in the hippocampus of mice lacking the Jnk3 gene , 1997, Nature.
[147] S. W. Davies,et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. , 1997, Science.
[148] A. Graybiel,et al. Neurochemical architecture of the human striatum , 1997, The Journal of comparative neurology.
[149] Mark Turmaine,et al. Formation of Neuronal Intranuclear Inclusions Underlies the Neurological Dysfunction in Mice Transgenic for the HD Mutation , 1997, Cell.
[150] C. Cain,et al. Cellular delivery of human CNTF prevents motor and cognitive dysfunction in a rodent model of Huntington's disease. , 1997, Cell transplantation.
[151] M. MacDonald,et al. CAG repeat number governs the development rate of pathology in Huntington's disease , 1997, Annals of neurology.
[152] M. Hayden,et al. The likelihood of being affected with Huntington disease by a particular age, for a specific CAG size. , 1997, American journal of human genetics.
[153] M. Beal,et al. Oxidative damage and metabolic dysfunction in Huntington's disease: Selective vulnerability of the basal ganglia , 1997, Annals of neurology.
[154] Y. Kawaguchi. Neostriatal cell subtypes and their functional roles , 1997, Neuroscience Research.
[155] W. Cass. Decreases in evoked overflow of dopamine in rat striatum after neurotoxic doses of methamphetamine. , 1997, The Journal of pharmacology and experimental therapeutics.
[156] M. Perutz,et al. Glutamine repeats and inherited neurodegenerative diseases: molecular aspects. , 1996, Current opinion in structural biology.
[157] P G Bhide,et al. Expression of Normal and Mutant Huntingtin in the Developing Brain , 1996, The Journal of Neuroscience.
[158] J. Kordower,et al. Implants of Encapsulated Human CNTF-Producing Fibroblasts Prevent Behavioral Deficits and Striatal Degeneration in a Rodent Model of Huntington’s Disease , 1996, The Journal of Neuroscience.
[159] Í. Lopes-Cendes,et al. Somatic mosaicism in the central nervous system in spinocerebellar ataxia type 1 and machado‐joseph disease , 1996, Annals of neurology.
[160] J. Xuereb,et al. The messenger RNAs for the N-methyl- d-aspartate receptor subunits show region-specific expression of different subunit composition in the human brain , 1996, Neuroscience.
[161] M. Mcdermott,et al. A controlled trial of remacemide hydrochloride in Huntington's disease , 1996, Movement disorders : official journal of the Movement Disorder Society.
[162] M. Beal,et al. Chronic 3-Nitropropionic Acid Treatment in Baboons Replicates the Cognitive and Motor Deficits of Huntington’s Disease , 1996, The Journal of Neuroscience.
[163] Charles J. Wilson,et al. The origins of two-state spontaneous membrane potential fluctuations of neostriatal spiny neurons , 1996, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[164] J. Cooper,et al. Mitochondrial defect in Huntington's disease caudate nucleus , 1996, Annals of neurology.
[165] A. Joyner,et al. Targeted inactivation of the mouse Huntington's disease gene homolog Hdh. , 1996, Cold Spring Harbor symposia on quantitative biology.
[166] Charles J. Wilson,et al. Striatal interneurones: chemical, physiological and morphological characterization , 1995, Trends in Neurosciences.
[167] E. Richfield,et al. Preferential loss of preproenkephalin versus preprotachykinin neurons from the striatum of Huntington's disease patients , 1995, Annals of neurology.
[168] S. Hersch,et al. Identification and localization of huntingtin in brain and human lymphoblastoid cell lines with anti-fusion protein antibodies. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[169] P. Calabresi,et al. Vulnerability of Medium Spiny Striatal Neurons to Glutamate: Role of Na+/K+ ATPase , 1995, The European journal of neuroscience.
[170] G. Landwehrmeyer,et al. NMDA receptor subunit mRNA expression by projection neurons and interneurons in rat striatum , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[171] S. Floresco,et al. Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes , 1995, Cell.
[172] E. Hirsch,et al. Cellular localization of the Huntington's disease protein and discrimination of the normal and mutated form , 1995, Nature Genetics.
[173] C. Portera-Cailliau,et al. Evidence for apoptotic cell death in Huntington disease and excitotoxic animal models , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[174] R. Carraway,et al. Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons , 1995, Neuron.
[175] I. Kanazawa,et al. Abnormal gene product identified in Huntington's disease lymphocytes and brain. , 1995, Biochemical and biophysical research communications.
[176] M. MacDonald,et al. Huntington's disease gene: Regional and cellular expression in brain of normal and affected individuals , 1995, Annals of neurology.
[177] A. Parent,et al. Functional anatomy of the basal ganglia. I. The cortico-basal ganglia-thalamo-cortical loop , 1995, Brain Research Reviews.
[178] S. Folstein,et al. Early Loss of Neostriatal Striosome Neurons in Huntington's Disease , 1995, Journal of neuropathology and experimental neurology.
[179] A. Reiner,et al. Relative Survival of Striatal Projection Neurons and Interneurons after Intrastriatal Injection of Quinolinic Acid in Rats , 1994, Experimental Neurology.
[180] T. Kuner,et al. Molecular biology of glutamate receptors , 1994, Progress in Neurobiology.
[181] B. McEwen,et al. Molecular aspects of neuropeptide regulation and function in the corpus striatum and nucleus accumbens , 1994, Brain Research Reviews.
[182] B. Rosen,et al. Evidence for irnnairment of energy metabofism in vivo in Huntington's disease using localized 1H NMR spectroscopy , 1993, Neurology.
[183] S. Folstein,et al. Huntington's disease gene (IT15) is widely expressed in human and rat tissues , 1993, Neuron.
[184] M. Beal,et al. Neurochemical substrates of rigidity and chorea in Huntington's disease. , 1993, Brain : a journal of neurology.
[185] B. Hyman,et al. Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid , 1993, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[186] J. Penney,et al. Trinucleotide repeat length instability and age of onset in Huntington's disease , 1993, Nature Genetics.
[187] M. MacDonald,et al. Relationship between trinucleotide repeat expansion and phenotypic variation in Huntington's disease , 1993, Nature Genetics.
[188] M. Hayden,et al. The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease , 1993, Nature Genetics.
[189] Manish S. Shah,et al. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes , 1993, Cell.
[190] O. Isacson,et al. Age dependence of striatal neuronal death caused by mitochondrial dysfunction. , 1993, Neuroreport.
[191] C. Gerfen. The neostriatal mosaic: multiple levels of compartmental organization , 1992, Trends in Neurosciences.
[192] J. Penney,et al. Preferential loss of striato‐external pallidal projection neurons in presymptomatic Huntington's disease , 1992, Annals of neurology.
[193] M. Beal,et al. Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses? , 1992, Annals of neurology.
[194] N. Kowall,et al. Neurofilament and neural cell adhesion molecule immunocytochemistry of Huntington's disease striatum , 1992, Annals of neurology.
[195] M. Hollmann,et al. Molecular neurobiology of glutamate receptors. , 1992, Annual review of physiology.
[196] Christopher A. Ross,et al. Neuronal loss in layers V and VI of cerebral cortex in Huntington's disease , 1991, Neuroscience Letters.
[197] N W Kowall,et al. Proliferative and degenerative changes in striatal spiny neurons in Huntington's disease: a combined study using the section-Golgi method and calbindin D28k immunocytochemistry , 1991, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[198] A. Ludolph,et al. 3-Nitropropionic Acid - Exogenous Animal Neurotoxin and Possible Human Striatal Toxin , 1991, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.
[199] R. S. Williams,et al. Morphometric analysis of the prefrontal cortex in Huntington's disease , 1991, Neurology.
[200] C. Gerfen,et al. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. , 1990, Science.
[201] A. Graybiel. Neurotransmitters and neuromodulators in the basal ganglia , 1990, Trends in Neurosciences.
[202] M. Cudkowicz,et al. Degeneration of pyramidal projection neurons in Huntington's disease cortex , 1990, Annals of neurology.
[203] J. Penney,et al. The functional anatomy of basal ganglia disorders , 1989, Trends in Neurosciences.
[204] Hitoshi Takahashi,et al. A quantitative investigation of the substantia nigra in Huntington's disease , 1989, Annals of neurology.
[205] P. Molinoff,et al. Basic Neurochemistry: Molecular, Cellular and Medical Aspects , 1989 .
[206] C. Gerfen. Synaptic organization of the striatum. , 1988, Journal of electron microscopy technique.
[207] A Jackson,et al. Chorea and myoclonus in the monkey induced by gamma-aminobutyric acid antagonism in the lentiform complex. The site of drug action and a hypothesis for the neural mechanisms of chorea. , 1988, Brain : a journal of neurology.
[208] C. Gerfen,et al. Distribution of striatonigral and striatopallidal peptidergic neurons in both patch and matrix compartments: an in situ hybridization histochemistry and fluorescent retrograde tracing study , 1988, Brain Research.
[209] J. Penney,et al. Differential loss of striatal projection neurons in Huntington disease. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[210] A. Crossman,et al. Primate models of dyskinesia: The experimental approach to the study of basal ganglia-related involuntary movement disorders , 1987, Neuroscience.
[211] R. Lasek,et al. Cytotypic differences in the protein composition of the axonally transported cytoskeleton in mammalian neurons , 1987, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[212] C. Gerfen,et al. The neostriatal mosaic: compartmental distribution of calcium-binding protein and parvalbumin in the basal ganglia of the rat and monkey. , 1985, Proceedings of the National Academy of Sciences of the United States of America.
[213] J. B. Martin,et al. Selective sparing of a class of striatal neurons in Huntington's disease. , 1985, Science.
[214] R. Ferrante,et al. Neuropathological Classification of Huntington's Disease , 1985, Journal of neuropathology and experimental neurology.
[215] J. Bouyer,et al. Chemical and structural analysis of the relation between cortical inputs and tyrosine hydroxylase-containing terminals in rat neostriatum , 1984, Brain Research.
[216] A. Parent,et al. The occurrence of large acetylcholinesterase-containing neurons in human neostriatum as disclosed in normal and Alzheimer-diseased brains , 1984, Brain Research.
[217] JohannesP. W. F. Lakke,et al. Classification of extrapyramidal disorders , 1981, Journal of the Neurological Sciences.
[218] R. A. Rodda,et al. Cerebellar atrophy in Huntington's disease , 1981, Journal of the Neurological Sciences.
[219] A. Parent,et al. Acetylcholinesterase-containing neurons in cat neostriatum: A morphological and quantitative analysis , 1980, Neuroscience Letters.
[220] T. Pasik,et al. Ultrastructure of Golgi-impregnated and gold-toned spiny and aspiny neurons in the monkey neostriatum , 1980, Journal of neurocytology.
[221] P. Mcgeer,et al. Duplication of biochemical changes of Huntington's chorea by intrastriatal injections of glutamic and kainic acids , 1976, Nature.
[222] T. Pasik,et al. A Golgi study of neuronal types in the neostriatum of monkeys , 1976, Brain Research.
[223] J. Coyle,et al. Lesion of striatal neurons with kainic acid provides a model for Huntington's chorea , 1976, Nature.
[224] K. F. Schroeder,et al. Morphometric studies of the neuropathological changes in choreatic diseases , 1976, Journal of the Neurological Sciences.
[225] F. Gilles,et al. Huntington's disease in children , 1973, Neurology.